Platform & Strategies
Publications
HomePlatform & StrategiesPublications
| NO | Pipeline | Name | Title | |
|---|---|---|---|---|
| 20 | ABL103 | PEGS Europe 2023 | PEGS Europe 2023 / ABL103, a novel B7-H4x4-1BB bispecific antibody, exerts potent antitumor activity and good safety profile via B7-H4-dependent 4-1BB activation with increased immune cell infiltration in tumor microenvironment |
|
| 19 | ABL102 | PEGS Europe 2023 | PEGS Europe 2023 / ROR1 targeted 4-1BB conditional bispecific antibody, ABL102, exhibits potent in vitro and in vivo antitumor activity and superior safety profile |
|
| 18 | Neuroscience | CVB2023 | CVB2023 / Grabody B, an IGF1 receptor based shuttle, mediates efficient delivery of biologics across the blood brain barrier |
|
| 17 | ABL102 | AACR2023 | AACR2023 / ROR1 Targeted 4-1BB Stimulatory Bispecific Antibody, ABL102, Exhibits Potent in vitro and in vivo Antitumor Activity and Superior Safety Profile |
|
| 16 | ABL205 | AACR2023 | AACR2023 / Preclinical study of a novel anti-CLEC12A antibody-drug conjugate with a glucuronideprotected pyrrolobenzodiazepine payload |
|
| 15 | ABL103 | AACR 2022 | AACR 2022 / A novel T-cell engaging bispecific antibody, exhibits potent in vitro and vivoantitumor activity and low toxicity via B7-H4 dependent 4-1BB activation in tumor microenvironment |
|
| 14 | ABL602 | ASH2021 | ASH2021 / A novel asymmetrical anti-CLL-1×CD3 bispecific antibody, ABL602, induces potent CLL1-specific antitumor activity with minimized sensitization of pro-inflammatory cytokines |
|
| 13 | ABL503 | SITC2021 | SITC2021 / ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8 + T cells in tumor microenvironment |
|
| 12 | ABL111 | SITC2021 | SITC2021 / TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumordependent immune response without dose-limiting toxicity in preclinical studies |
|
| 11 | ABL103 | PEGS Europe 2021 | PEGS Europe 2021 / A novel T-cell engaging bispecific antibody, ABL103, shows potent anti-tumor effect via B7-H4 mediated 4-1BB activation in TME |
|
-
PEGS Europe 2023 / ABL103, a novel B7-H4x4-1BB bispecific antibody, exerts potent antitumor activity and good safety profile via B7-H4-dependent 4-1BB activation with increased immune cell infiltration in tumor microenvironment
-
PEGS Europe 2023 / ROR1 targeted 4-1BB conditional bispecific antibody, ABL102, exhibits potent in vitro and in vivo antitumor activity and superior safety profile
-
CVB2023 / Grabody B, an IGF1 receptor based shuttle, mediates efficient delivery of biologics across the blood brain barrier
-
AACR2023 / ROR1 Targeted 4-1BB Stimulatory Bispecific Antibody, ABL102, Exhibits Potent in vitro and in vivo Antitumor Activity and Superior Safety Profile
-
AACR2023 / Preclinical study of a novel anti-CLEC12A antibody-drug conjugate with a glucuronideprotected pyrrolobenzodiazepine payload
-
AACR 2022 / A novel T-cell engaging bispecific antibody, exhibits potent in vitro and vivoantitumor activity and low toxicity via B7-H4 dependent 4-1BB activation in tumor microenvironment
-
ASH2021 / A novel asymmetrical anti-CLL-1×CD3 bispecific antibody, ABL602, induces potent CLL1-specific antitumor activity with minimized sensitization of pro-inflammatory cytokines
-
SITC2021 / ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8 + T cells in tumor microenvironment
-
SITC2021 / TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumordependent immune response without dose-limiting toxicity in preclinical studies
-
PEGS Europe 2021 / A novel T-cell engaging bispecific antibody, ABL103, shows potent anti-tumor effect via B7-H4 mediated 4-1BB activation in TME